Jump to content

KF-26777

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Dcirovic (talk | contribs) at 14:09, 1 June 2016 (Unicodifying using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

KF-26777
Clinical data
Other namesKF-26777
Identifiers
  • (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H18BrN5O
Molar mass376.250 g/mol g·mol−1
3D model (JSmol)
  • CCCN(C2=O)C1N=C(c(cc3)ccc3Br)NC1C=4N2CCN=4
  • InChI=1S/C16H16BrN5O/c1-2-8-21-15-12(14-18-7-9-22(14)16(21)23)19-13(20-15)10-3-5-11(17)6-4-10/h3-6H,2,7-9H2,1H3,(H,19,20)
  • Key:GYGNZJDWTHECQT-UHFFFAOYSA-N
  (verify)

KF-26777 is a drug which acts as a potent and selective antagonist for the adenosine A3 receptor, with sub-nanomolar affinity (A3 Ki=0.2nM) and high selectivity over the other three adenosine receptor subtypes.[1] Simple xanthine derivatives such as caffeine and DPCPX have generally low affinity for the A3 subtype and must be extended by expanding the ring system and adding an aromatic group to give high A3 affinity and selectivity.[2]

References

  1. ^ Saki M, Tsumuki H, Nonaka H, Shimada J, Ichimura M (May 2002). "KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist". European Journal of Pharmacology. 444 (3): 133–41. doi:10.1016/S0014-2999(02)01662-X. PMID 12063073.
  2. ^ Baraldi PG, Tabrizi MA, Gessi S, Borea PA (January 2008). "Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility". Chemical Reviews. 108 (1): 238–63. doi:10.1021/cr0682195. PMID 18181659.